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Abstract: Phospholipase A2 (Pla2) is an enzyme that induces inflammation, making Pla2 activity
an effective approach to reduce inflammation. Therefore, investigating natural compounds for
this Pla2 inhibitory activity has important therapeutic potential. The objective of this study was
to investigate the potential in bromelain-phytochemical complex inhibitors via a combination of
in silico and in vitro methods. Bromelain-amenthoflavone displays antagonistic effects on Pla2.
Bromelian-asiaticoside and bromelain-diosgenin displayed synergistic effects at high concentrations
of the combined compounds, with inhibition percentages of more than 70% and 90%, respectively,
and antagonistic effects at low concentrations. The synergistic effect of the bromelain-asiaticoside
and bromelain-diosgenin combinations represents a new application in treating inflammation.
These findings not only provide significant quantitative data, but also provide an insight on
valuable implications for the combined use of bromelain with asiaticoside and diosgenin in treating
inflammation, and may help researchers develop more natural bioactive compounds in daily foods
as anti-inflammatory agent.
Keywords: combination index; bromelain; phospholipase A2; anti-inflammatory agent; phytochemical
1. Introduction
Inflammation is a complex process involving many cell types and it acts as a body-protective response
to injury, infections, cell damage and irritants. An inflammatory disorder occurs when inflammation
becomes uncontrolled and causes damage to healthy tissues. For example, the inflammation pathway in
adipose tissues is used for energy storage and lipid homeostasis, but the imbalance of food intake and
expenditure leads to obesity. The discovery of obesity as an inflammatory state prompted researchers
to explore the mechanism of inflammation related to obesity. Thus, researchers have investigated
anti-inflammatory agents for the treatment of obesity. Bromelain was proven to be anti-inflammatory
inhibitor by irreversibly inhibiting 3T3-L1 in adipogenesis by reducing adipogenic gene expression and
inducing apoptosis and lipolysis in mature adipocytes [1].
Phospholipase A2 (Pla2) is a rigid tertiary structure enzyme with approximately eight disulfide
bonds that can protect from heat denaturation and proteolysis [2]. This enzyme hydrolyzes the
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sn-2 ester bond of glycerophospholipids for the liberation of free fatty acids and lysophospholipids
molecules [3]. To date, eleven Pla2 compounds belonging to groups IB, IIA, IIC, IID, IIE, IIF, III, V, X,
XIIA, and XIIB have been characterized in mammals. The IIA group has been identified to contribute
to the initiation of inflammation which subsequently induces the section of arachidonic acid and
leads to the formation of inflammation mediators [4]. Arachidonic acid is metabolized either by
the cyclo-oxygenase or lipo-oxygenase enzymatic pathway for the production of diverse families of
eicosanoids such as prostaglandins and leukotrienes, which are primarily involved in the inflammatory
pathway [4]. Meanwhile in reptiles, venomous snakes secret three groups of Pla2 enzymes, including
IA, IIA, and IIB, which are responsible for several pathological manifestations of envenomation, such
as inflammation and toxicity [4]. An excess level of Pla2 promotes multiple diseases related to vascular
inflammation, such as coronary artery disease and acute coronary syndrome [5].
Recent studies have discovered several natural compounds that possess inhibitory activity against
Pla2 [6,7]. However, treatment with a single anti-inflammatory drug often causes multiple adverse
effects such as hepatoxicity, gastrointestinal haemorrhage, meningitis and asthma [8]. Therefore,
a novel strategy combining two or more potential compounds that exhibit inhibitory effects against
Pla2 activity has been proposed to overcome the problem. Additionally, this approach has previously
been shown to enhance the thermal stability of the combination [9].
Bromelain and phytochemicals like amenthoflavone, asiaticoside, and diosgenin have been
reported to exhibit inhibitory effects against Pla2 activity [7,10–12]. Bromelain, asisticoside and
diosgenin appear to be safe compounds, as they do not show any toxic effects with a lethal dose (LD50)
of up to 750 mg/kg in dogs, 50 mg/kg in mice and more than 8000 mg/kg in mice, respectively [13–15].
It was also discovered that the combination of phytochemical compounds with bromelain could
enhance the functional properties and thermal stability and increase the shelf life of pineapple
juice [9,16]. The combinations with natural products, including bromelain, was also proven to enhance
the effect of other anti-inflammatory drugs such as paracetamol in the relief of the knee joint pain [17].
The effect of the combination between bromelain and antibiotics was shown to be more effective
compared to antibiotics alone in the treatment of pneumonia, bronchitis and cellulitis [18].
In this study, the synergistic potential of combinations of bromelain and phytochemicals namely,
amenthoflavone, asiaticoside, and diosgenin, against Pla2 was quantified. The combinations of
bromelain-amenthoflavone (Br-Am), bromelain-asiaticoside (Br-As), and bromelain-diosgenin (Br-Di)
were analyzed using a protocol developed by Chou and Talalay [19], which is widely used to determine
the synergistic and antagonistic effects in combination studies. Subsequently, proof of the utility of the
bromelian-phytochemical complex were generated by measuring the inhibitory activity against Pla2.
2. Results
2.1. Top Ten Ranking Compounds and Molecular Docking Results
The current study aimed to select and investigate the natural compounds isolated from Malaysian
herbs (Mherb) that are able to form strong and stable bonds with bromelain using a virtual screening
approach. Final docked conformations had ranked 10 NADI compounds from highest to lowest ∆G of
the binding energy as listed in Table 1. The more negative the ∆G values, the stronger the binding
between a protein and a ligand. Among these 10 compounds only three compounds—amenthoflavone,
asiaticoside and diosgenin—were selected for further preliminary experimental validation. Figure 1
shows the chemical structure of these compounds. The selection of these three compounds was based
on the availability of the compounds.
Figure 2 shows the binding site for the docked conformation of bromelain with amenthoflavone,
asiaticoside and diosgenin. It was seen that these compounds bound at the same binding region,
indicate a similar potential for stabilization of the enzyme. Even though these compounds bound at
the same binding region, they showed somewhat different binding orientations. The hydroxyl (OH)
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substituent was found to interact with polar residues, while the aromatic rings of the compounds were
found to be buried in the hydrophobic site.
Table 1. Top 10 compounds from the NADI database after virtual screening against bromelain.
Rank Compound Name Binding Affinity (∆G) (kcal/mol) Plant
1 A-Viniferin −11.3 Shorea gibbosa
2 Gnetin E −11.3 Gnetum gnemonoside
3 Isorhoifolin −11.1 Theobroma cacao
4 Lupenone −11.0 Murraya paniculata
5 Amenthoflavone −11.0 Garcinia prainiana
6 Diosgenin −10.8 Costus speciousus
7 Echinocyctic acid −10.7 Eclipta prostata
8 Smilagenin −10.7 Trigonella foenum
9 Asiaticoside −10.7 Centella asiatica
10 Friedelin −10.6 Lawsonia inermis
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In this study, the binding mode patterns of the compounds were investigated based on their
hydrogen bonding and hydrophobic interactions. Amenthoflavone formed eight hydrogen bonds and
nine hydrophobic interactions (Figure 3). However there was no occurrence of hydrogen bond for
the bromelain and diosgenin complex, but diosgenin formed hydrophobic interactions with fourteen
bromelain residues which were Lys61, Phe62, Val112, Thr113, Glu114, Val115, Lys116, Gln118, Cys124,
Phe127, Ala131, His127, Ala258, and Thr260 (Figure 4).
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All these residues were almost the same as the residues that formed hydrophobic contacts with
amenthoflavone. Diosgenin did not mediate any hydrogen bonds, and the binding energy between
this compound and bromelain was found to be the lowest. This is probably due to the formation
of the hydrophobic contacts which contributed to the stability of the docked conformation between
bromelain and diosgenin. Figure 5a showed the hydrogen bond contacts of asiaticoside with residues
Thr113, Lys116, Gln118 and Tyr264 of bromelain. Asiaticoside also formed a network of hydrophobic
contacts with residues Lys61, Phe62, Tyr74, Val112, Glu114, Val115, Asp117, Phe127, Ser128, Ala131,
Ile232, Phe239, Tyr242, His257, Ile259, Ile261, Gly265, THR260, and Ile262 (Figure 5b). Asiaticoside
showed the highest numbers of hydrophobic contacts. It is also the bulkiest structure compared to the
other two compounds.
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2.2. Inhibitory Activity of Bromelain, Amenthoflavone, Asiaticoside, and Diosgenin against Pla2
The selected compounds were further evaluated for their inhibitory activity of Pla2. As presented
in Figure 6, all tested compounds showed a dose-dependent inhibitory activity against Pla2. Gallic acid
was used as a positive control in order to support the method used for Pla2 inhibition. Bromelain and
amenthoflavone at 1 mg/mL produced the highest inhibitory of 80% and 83%, respectively, followed
by asiaticoside (60%) and diosgenin (45%).
olecules 2018, 23, 73  5 of 13 
 
 
Figure 5. I lustrations of the hydrogen bonds and hydrophobic contacts bet een bro elain and 
asiaticoside. (a) ydrogen bond interactions bet een asiaticoside (stick) and bro elain odel (line 
ribbon). Residues that involved in hydrogen bond interactions are sho n in stick odel; (b) 
hydrophobic interactions bet een asiaticoside (stick) and bro elain odel (line ribbon). Residues 
that involved in hydrophobic interactions are sho n in P  odel. 
2.2. Inhibitory ctivity of Bro elain, enthoflavone, siaticoside, and iosgenin gainst Pla2 
The selected co pounds ere further evaluated for their inhibitory activity of Pla2. s 
presented in Figure 6, a l tested co pounds sho ed a dose-dependent inhibitory activity against 
Pla2. a lic acid as used as a positive control in order to support the ethod used for Pla2 
inhibition. Bro elain and a enthoflavone at 1 g/ L produced the highest inhibitory of 80  and 
83 , respectively, fo lo ed by asiaticoside (60 ) and diosgenin (45 ). 
 
Figure 6. Inhibition of Pla2 activity by bro elain, a enthoflavone, asiaticoside, and diosgenin. 
The dose effect of bro elain, a enthoflavone, asiaticoside and diosgenin as applied in a 
edian-effect plot for the deter ination of the fo lo ing potential para eters: edian effect dose 
at 50  inhibition ( m), slope of edian effect plot ( ), and linear correlation coefficient (rc) in Pla2 
inhibitory activity. Table 2 sho s that the m values of bro elain, a enthoflavone, asiaticoside, 
and diosgenin ere 0.0723, 0.1078, 0.3143 and 0.9659 g/ L, respectively. The r values ere greater 
than 0.95, indicating that this in vitro study is acceptable. The m and  values for a single 
co pound and their co bination ixture ere used for the calculation of I through Equation (5) 
in Section 4.5 belo . 
i . I i iti f l ti it l i , t fl , i ti i , i i .
The dose effect of bro elain, amenthoflavone, asiaticoside and diosgenin was applied in
a median-effect plot for the deter ination of the following potential para eters: edian effect dose
at 50% inhibition (Dm), slope of edian effect plot (m), and linear correlation coefficient (rc) in Pla2
inhibitory activity. Table 2 shows that the Dm values of bromelain, amenthoflavone, asiaticoside, and
diosgenin were 0.0723, 0.1078, 0.3143 and 0.9659 mg/mL, respectively. The r values were greater than
0.95, indicating that this in vitro study is acceptable. The Dm and m values for a single compound and
their combination mixture were used for the calculation of CI through Equation (5) in Section 4.5 below.
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Table 2. Dose–effect relationship parameters of Br-Am, Br-As, and Br-Di combinations and single
compounds against Pla2.
Compound Dm (mg/mL) a m b r c
Bromelain 0.0723 0.6767 ± 0.0450 0.9879
Amenthoflavone 0.1079 0.4480 ± 0.0489 0.9968
Asiaticoside 0.3143 0.5258 ± 0.0381 0.9846
Diosgenin 0.9659 0.7018 ± 0.0229 0.9659
Bromelain (Br) + amenthoflavone (Am)
0.6093
(Br = 0.2437 mg/mL)
(Am = 0.3655mg/mL)
- -
Bromelain (Br) + asiaticoside (As)
0.311
(Br = 0.020 mg/mL)
(As = 0.2911 mg/mL)
- -
Bromelain (Br) + diosgenin (Di)
3.0603
(Br = 0.1500 mg/mL)
(Di = 2.9103 mg/mL)
- -
aDm is the median-effect dose required for 50% inhibition calculated from compusyn software; b m is the coefficient
of the sigmoidicity/shape of dose-effect curve; c r is the significant coefficient that should be more than 0.95.
2.3. Combined Effects of Phytochemicals and Bromelain against Pla2
Among the combinations, Br-As showed the highest inhibitory activity because it required the
lowest concentration (0.311 mg/mL; Table 2). The concentration of the combination between bromelain
and asiaticoside was less than that of the concentration at IC50 of a single compound (either bromelain
or asiaticoside). We used dose-effect curves and CI methods to investigate the combined effects of
Br-Am, Br-As, and Br-Di against Pla2, and the results are summarized in Figures 7–9. Figure 7 shows
that the combination of bromelain and amenthoflavone displayed an antagonistic effect on Pla2 at
the concentration used in the experiment. The CI value was near the additive effect line when the
percent inhibition and concentration of the complex was high. Figure 8 shows that the Br-As complex
exhibited a synergistic effect when the inhibition percentage was more than 70%.
At the inhibition percentage of approximately 70%, the combination Br-As was additive. However,
the combined effect changed to antagonism at low inhibition levels (<70%). Meanwhile, the Br-Di
complex showed a synergistic effect when the inhibition percentage was more than 90%. According
to the results in Figures 7–9, the combinations of bromelain with amenthoflavone, asiaticoside,
or diosgenin were synergistic at high concentrations and antagonistic at low concentrations.
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DRI values (Table 3) indicated that the combination of Br-As and Br-Di showed a favorable
combination from IC50 to IC95 and IC90 to IC95, respectively. Meanwhile, no favorable DRI value was
obtained from the combination between bromelain and amenthoflavone.
Table 3. DRI values of singles compound, Br-Am, Br-Aa, and Br-Di at 50%, 75%, 90% and 95% inhibition
of Pla2.
Compound Combination
DRI V lue +
IC50 IC75 IC90 IC95
Bromel in (Br) + amenthoflavone (Am) 0.29 (Br) 0.29 (Am) 0.48 (Br) 0.44 (Am) 0.76 (Br) 0.68 (Am) 1.06 (Br) 0.90 (Am)
Bromelain (Br) + asi ticoside (As) 1.14 (Br) 1.07 (As) 2.36 (Br) 3.55 (As) 4.87 (Br) 11.7 (As) 8.00 (Br) 26.35 (As)
Bromelain (Br) + diosgenin (Di) 0.84 (Br) 0.70 (Di) 0.77 (Br) 2.58 (Di) 1.22 (Br) 9.42 (Di) 1.68 (Br) 22.73 (Di)
+ DRI represents the order of magnitude (fold) of dose reduction that is allowed in reduction. DR < 1 and DRI > 1
indicate non-favorable and favorable, respectively.
3. Discussion
Molecular docking is a powerful bioinformatics tool to gain insight into the most probable
binding conformation of phytochemicals, which in return helps explain the reasons for their potency.
Observing the structural features such as the position of aromatic rings and hydroxyl substituents (OH)
on phytochemicals is essential in order to further understand the molecular interactions. Furthermore,
the orientations of each compounds in the binding site are influenced by the hydrophobic and hydrogen
bond interactions. Compounds that have more aromatic rings tend to interact with hydrophobic
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residues, while, compounds that have more OH substituents tend to form more hydrogen bonds.
For example, amenthoflavone and asiaticoside formed more hydrogen bonds due to their bulkier
structures that contain more OH substituents. The docking results also indicated that the active
compounds can be stabilized in the binding site through hydrophobic interactions. Bdira and
co-workers reported similar results suggesting the hydrophobic interactions with an aliphatic tail can
influence protein stabilization and rigidification [20].
Bromelain, an enzyme that found abundantly in pineapple has been suggested as one of the most
effective anti-inflammation agents with adequate toxicology and safety testing data as well as multiple
biological activities [13]. However, bromelain is degraded at high temperatures, thus affecting the
enzyme efficiency. The hydrophobic interactions produced a rigid protein structure which is difficult to
denature by high temperature. Our results displayed the binding pocket of bromelain was surrounded
by mostly hydrophobic residues and for that reason, all three of the compounds formed hydrophobic
contacts in the binding pocket. This rationalized the study hypothesis regarding the interactions
of phytochemicals and bromelain could enhance the stability of bromelain and increase the shelf
lifetime. Furthermore, all tested compounds were favored to form hydrophobic conditions due to the
presence of aromatic rings. These compounds bound in the hydrophobic pocket of bromelain, thus
forming rigid hydrophobic-hydrophobic interactions. Collectively, this study suggested that the high
thermal stability of bromelain-phytochemical complex was a result of the presence of hydrophobic-
hydrophobic interactions.
Compounds that enhance protein thermostability have been associated with anti-inflammatory
activities [21]. Based on the docking results, the developed bromelain-phytochemical complexes were
subsequently analysed for its anti-inflammatory activity against Pla2. The results can facilitate the
discovery of drug combinations that have a synergistic effect against the Pla2 activity. Bromelain-
diosgenin complex presented a promising synergistic effect, with 90% inhibition of Pla2 despite the
low anti-inflammatory activity of diosgenin. It showed a substantial additive effect when combined
with bromelain. Meanwhile, the bromelain-asiaticoside complex displayed the most synergistic
combination as the synergism was initiated at 70% inhibition. The DRI value for this combination
required 1.12-fold less bromelain and 1.07-fold less asiaticoside at 50% inhibition. This value could
be used as a guideline for the reduction of the toxicity effect on normal tissues and maximize the
therapeutic effect. Unfortunately, antagonistic effect was observed on the combination of bromelain
and amenthoflavone, possibly due to the mechanism of these compounds toward Pla2. Synergistic
effects of natural product combinations can be affected by several factors such as the pharmacokinetics,
physicochemical properties, complex multitarget effects and therapeutic approaches [22].
Natural compounds with good inhibitory activity on Pla2 and low cytotoxicity are useful for
potential therapeutic applications. The anti-inflammatory activity of plant extracts above 70% at
250 mg/mL concentration is considered significant [23]. Of the three combinations, only Br-As and
Br-Di led to dose-dependent Pla2 inhibition. Moreover, the combinations between bromelain and
polyphenolic compounds enhanced the thermal stability of bromelain [9]. Furthermore, bromelain
alone was easily denatured when the temperature is more than 50 ◦C, but the compound containing
bromelain and polyphenol remained stable at this temperature. Therefore, the combinations between
bromelain and phytochemical are potential anti-inflammatory agents. The synergistic effect of
many compounds in natural products also enhanced their antioxidant activities because antioxidant
compound will scavenge the free radicals produced from inflammation [24] and anti-inflammatory
agents modulate the activities of proinflammatory enzymes and cytokines. During inflammation,
eicosanoids, as proinflammatory mediators, are synthesized through Pla2 hydrolysis. The inhibitory
activity of eicosanoid production from natural compounds may be induced by the inhibition of Pla2
enzyme activity. Many natural compounds are known inhibitors of Pla2 expression [25,26]. Meanwhile,
the inhibitory activity of the combination between bromelain and phytochemical compounds on Pla2
remains unreported. Thus, the combination among Br-Am, Br-As, and Br-Di was selected because of
the role bromelain plays in inflammation treatment and enhancement of functional properties when
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combined with phytochemical compounds. This combination can display synergistic activity and
increase the therapeutic efficacy. Alternatively, these combinations; Br-Am, Br-As, and Br-Di might
be used as food sources for treating inflammation instead of typically used synthetic drug therapy.
It would be interesting to further investigate the effects of these complexes as the anti-inflammatory
agent on a simple cell system such as mouse macrophages for evaluation purposes.
The intake of pineapple juice rich in bromelain can be potentially used as a therapy for
inflammation disorders. Meanwhile, the combination between bromelain and phytochemicals that
showed synergistic effect might be useful in treating inflammation because of the stability of bromelain
and phytochemical complexes. This stability is useful in preserving the lifetime of the mixture.
Furthermore, the shelf life of pineapple juice (source of bromelain) and polyphenol mixture is longer
compared with that of pineapple juice alone [16]. Polyphenols act as antioxidant agents stabilizing the
pineapple juice. Bromelain alone tends to be easily oxidized and denatured without an antioxidant
agent. Dietary interference wherein naturally bioactive compounds in daily foods are used might
be a more practical approach than the application of chemical therapy. Intake of asiaticoside and
diosgenin accompanied by a certain amount of bromelain might be more efficient compared with these
compounds alone because some phytochemicals are poorly absorbed and distributed in therapeutic
application. Thus, the poor bioavailability of phytochemicals affects the effective dose delivered to the
target cells/protein [27]. Even though natural products are typically known to be safe, it is challenging
to determine the efficacy profile of these products due to the increment of the toxicity effects [28].
One of the implications of this study is that various experiments must be conducted to determine
the optimum concentration of the combination complexes that are safe for use as a treatment for
a disease. This combination must be done up to in vivo study in order to validate the efficiency of
the combinations.
4. Materials and Methods
4.1. Materials
Bromelain, diosgenin, asiaticoside, porcine group IB phospholipase A2 (pG-IB), egg yolk
phosphatidylcholine, red phenol, sodium taurodeoxycholate (NaTDC), and potassium phosphate were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Amenthoflavone was purchased from Atkins
Chemicals (Chengdu, China).
4.2. Virtual Screening
4.2.1. Protein and Ligand Library Preparation
The homology model of bromelain molecule was developed in previous research. The bromelain
model was prepared using Autodock Tool (ADT) [29]. Hydrogen atoms were added to the receptor
using ADT. Kollman charges were assigned and solvation parameters were added to this enzyme
molecule. The grid binding box was centered at 48× 167× 63 and the size created with the dimensions
of 34 × 36 × 32 with the default spacing is 1 Å. AutoGrid was used to create the affinity grids which
focus at the active sites. The three dimensional (3D) structures of 4071 Malaysian natural compounds
were obtained from the NADI database (www.nadi-discovery.com). Structures of these compounds
were generated using Schrödinger’s LigPrep module [30]. In brief, protonation states were assigned at
pH 7.0 using Epik. For each compound, LigPrep identified all tautomeric, one stereoisomeric state, and
one low energy ring conformation. The structure were optimized using OPLS_2005 force field. NADI
database were prepared for docking calculations using Raccoon [31] which added the Gasteiger-Marsili
chargers, merged the non-polar hydrogen atoms onto their respective heavy atoms and generate the
“pdbqt” docking input format for each compound.
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4.2.2. Molecular Docking
The virtual screening and docking was performed using AutoDock Vina [32]. Autodock Vina was
used due to its accuracy and speed. AutoDock Vina was utilized to automate the docking process
towards the NADI compounds. The predicted binding energy (∆G), which indicates the strength of
compounds bind to the receptor is calculated based on scoring function used in Autodock Vina. The top
ten docking conformations for each compound was selected using a Python script file. The selection
was based on lowest energy binding. The H-bond, and hydrophobic interaction were analysed using
ligplot server [33] and viewed using and Discovery studio visualizer.
4.3. Inhibition of Pla2 Activity
The inhibitory activity of Pla2 was tested according to the method described by De Aranjo and
Radvany [34]. Briefly, the substrate consisted of 3.5 mM lecithin, a mixture of 3 mM NaTDC, 100 mM
NaCl, 10 mM CaCl2, and 0.055 mM red phenol as colorimetric indicator, and 100 mL H2O. The pH
of the reaction mixture was adjusted to 7.6. 0.2 µg of pG-IB was solubilized in 10% acetonitrile at
a 0.002 µg/µL concentration. A volume of 2 µL of Pla2 solution was incubated with 2 µL of sample
for 20 min at room temperature. Then, 200 µL of Pla2 substrate was added to the solution. Kinetic
hydrolysis was performed for 5 min, and optical density was read at 558 nm. The Pla2 inhibitory
activity was expressed in inhibition percentage and was calculated as follows:
Enzyme activity =
ODzero − OD15 min
15 min
(1)
% inhibition =
enzyme activity−ve control − enzyme activitysample
enzyme activity−ve control
× 100 (2)
4.4. Experimental Design of Combination Study
An experimental design was formulated for the evaluation of the effect of phytochemical compounds
(amenthoflavone, asiaticoside, and diosgenin) combined with bromelain. First, the IC50 values of
amenthoflavone and bromelain were calculated on the basis of dose-response curves. Subsequently,
six concentrations of amenthoflavone at 2.5 IC50, 2 IC50, IC50, 0.5 IC50, and 0.2 IC50 was prepared and
combined with equal concentration (2.5 IC50, 2 IC50, IC50, 0.5 IC50, and 0.2 IC50) of bromelain at equal
volume. The inhibitory effects of combined bromelain and amenthoflavone were examined on Pla2.
The same experimental design described above was repeated for combination of Br-As and Br-Di. Table 4
shows the series of concentration of each bromelain-phytochemical complex.
Table 4. The concentration of each bromelain-phytochemical complex.
Compounds
Concentration (mg/mL)
2.5 IC50 2 IC50 1 IC50 0.5 IC50 0.2 IC50
Bromelain 0.1808 0.1446 0.0723 0.03615 0.01445
Amenthoflavone 0.2698 0.2158 0.1079 0.0540 0.0216
Asiaticoside 0.7858 0.6286 0.3143 0.1572 0.0628
Diosgenin 2.4148 1.9308 0.9659 0.4829 0.1932
4.5. Median Effect, Combination Index (CI), and Dose Reduction Index Analysis
To correctly estimate the combination effects (synergism, additive, and antagonism) of compounds,
we applied the median-effect principle and CI developed by Chou and Talalay [19]. The median-effect
equation is as follows:
fa
fu
=
(
D
Dm
)m
(3)
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In Equation (1), D is the dose, Dm is the dose required for 50% inhibition, fa is the fraction effected
by dose D, m is a coefficient of the sigmoidicity of dose-effect curve, and fu is the unaffected fraction
(fa = 1 − fu). A rearrangement of Equation (1) gives:
D = Dm[ fa/(1− fa)]
1
m (4)
CI is expressed as:
CI =
(D)1
(Dx)1
+
(D)2
(Dx)2
(5)
We used the dose reduction index (DRI) to determine whether the combination can result in
a reduction-compound dose. Dose reduction is important because it can reduce toxicity and maintain
or increase the main therapeutic efficacy. Favorable DRI values would be >1, whereas unfavorable
ones would be <1.
4.6. Statistical Analysis
All data were expressed in mean ± SEM. Statistical analysis was performed using the SPSS
program (V.18.0, IBM Corp., Armonk, NY, USA) with one way ANOVA and Tukey test. Significant
difference was considered as p < 0.05.
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